March 10, 2014 | Israeli company XTL Biopharmaceuticals, which is focused on developing a treatment for lupus, has filed with the US Securities and Exchange Commission (SEC) to hold a public offering on Nasdaq in an attempt to raise $40 million. The proceeds will be directed towards various clinical trials the company is planning.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

$10M For Cyber Company That Protects Small Businesses
January 31, 2023

Phone-Block Technology For School Bus Drivers
January 31, 2023

Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023

People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments